Faron Pharmaceuticals Oy (LSE:FARN) ROCE %: -911.79% (As of Dec. 2025)


LSE:FARN Faron Pharmaceuticals Oy LSE:FARN
22 GF Score
Price £0.41
! 4 Warning Signs
View Full Analysis

What is Faron Pharmaceuticals Oy ROCE %?

Faron Pharmaceuticals Oy LSE:FARN -0.24% 22 ROCE % is -911.79% as of Dec. 2025. GuruFocus rates LSE:FARN with a GF Score™ of 22/100. The stock has 4 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Faron Pharmaceuticals Oy's annualized ROCE % for the quarter that ended in Dec. 2025 was -911.79%.

Faron Pharmaceuticals Oy  (LSE:FARN) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Faron Pharmaceuticals Oy ROCE % Related Terms

Faron Pharmaceuticals Oy ROCE % Historical Data

* Premium members only.

The historical data trend for Faron Pharmaceuticals Oy's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Faron Pharmaceuticals Oy ROCE % Chart

Faron Pharmaceuticals Oy Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROCE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -524.76 -820.84 0.00 0.00 -9,925.33

Faron Pharmaceuticals Oy Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 -564.28 -328.56 -424.00 -911.79
LSE:FARN
22GF Score
Faron Pharmaceuticals Oy LSE:FARN
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Faron Pharmaceuticals Oy ROCE % Calculation

Faron Pharmaceuticals Oy's annualized ROCE % for the fiscal year that ended in Dec. 2025 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=-22.729/( ( (10.371 - 8.424) + (15.02 - 16.509) )/ 2 )
=-22.729/( (1.947+-1.489)/ 2 )
=-22.729/0.229
=-9,925.33 %

Faron Pharmaceuticals Oy's ROCE % of for the quarter that ended in Dec. 2025 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Dec. 2025 )  (Q: Jun. 2025 )(Q: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Dec. 2025 )  (Q: Jun. 2025 )(Q: Dec. 2025 )
=-25.676/( ( (13.774 - 6.653) + (15.02 - 16.509) )/ 2 )
=-25.676/( ( 7.121 + -1.489 )/ 2 )
=-25.676/2.816
=-911.79 %

(1) Note: The EBIT data used here is two times the semi-annual (Dec. 2025) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of -911.79% mean?
Faron Pharmaceuticals Oy (LSE:FARN) has a ROCE % of -911.79% as of Dec. 2025.
Is Faron Pharmaceuticals Oy's ROCE % too high?
Faron Pharmaceuticals Oy's current ROCE % is -911.79%. Overall, Faron Pharmaceuticals Oy has a GF Score™ of 22/100, reflecting its overall financial health beyond just this single metric.
How does Faron Pharmaceuticals Oy's ROCE % compare to VRTX and REGN?
Faron Pharmaceuticals Oy's ROCE % of -911.79% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Biotechnology company?
A good ROCE % depends on the Biotechnology industry context. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. Faron Pharmaceuticals Oy's current ROCE % is -911.79%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Faron Pharmaceuticals Oy stock overvalued right now?
Faron Pharmaceuticals Oy (LSE:FARN) has a current ROCE % of -911.79%. The current ROCE % is -911.79%. Faron Pharmaceuticals Oy's overall GF Score™ is 22/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Faron Pharmaceuticals Oy (LSE:FARN), the current ROCE % is -911.79% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Faron Pharmaceuticals Oy Business Description

Other Exchanges FARON:Finland4FR:Germany
Address Joukahaisenkatu 6 B, Turku, FIN, 20520
Faron Pharmaceuticals Oy is a clinical-stage biopharmaceutical company. The company has one operating and reportable segment. The Group has a pipeline based on the receptors involved in the regulation of immune response in oncology, organ damage, and bone marrow regeneration. Faron is a late clinical stage drug discovery and development Group. The company includes Bexmarilimab in its pipeline. Bexmarilimab is Faron's wholly owned, investigational immunotherapy designed to overcome resistance to existing treatments and improve clinical outcomes by targeting myeloid cell function in the microenvironment and igniting the immune system against cancer.
22GF Score

Get the complete analysis for LSE:FARN

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

£0.41
Price